Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

Precision medicine, also known as personalised medicine, is transforming healthcare by providing tailored treatments to patients suffering from life-threatening conditions. We are all unique, and ...

Transitioning from my role as a pharmacist to becoming a project manager in healthcare technology was not just a professional milestone, but a deeply transformative journey. As a pharmacist, I saw ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Drug development is a high-stakes, high-cost endeavour. Every new drug entering clinical trials requires careful decision-making, particularly regarding trial design and resource allocation.

Trade bodies representing the European prescription and over-the-counter pharma sectors have issued a call to action to regulators, asking them to accelerate the adoption of electronic product ...

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to AstraZeneca's Tagrisso in a head-to-head trial, claiming what could be a key ...

As of late November 2024, the US Food & Drug Administration had recorded 46 voluntary drug recalls in the United States during the year, down slightly from previous years – an indication that ...

Welcome to the last edition of Changing Faces for 2024. With the holiday season limiting the December announcements, we chose to combine our November and December editions to bring you a ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is ...